Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 11/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 11/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.48 |
| ▸ | CHRNB3 | Q05901 | 5/20 | 0.42 |
| ▸ | CHRNA6 | Q15825 | 5/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2673551 | 1.00 | CHRNB2 (0.48) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL2673131 | 1.00 | CHRNB2 (0.48) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL29626585 | 0.88 | CHRNB2 (0.50) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL2146232 | 0.87 | CHRNB2 (0.43) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL2148977 | 0.87 | CHRNB2 (0.43) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL2146324 | 0.86 | CHRNB2 (0.42) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL24341885 | 0.84 | HPGD (0.52) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL24312822 | 0.83 | CHRNB2 (0.55) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL10309699 | 0.78 | NOS2 (0.37) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL26118826 | 0.77 | PDK2 (0.41) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450271-B | Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition | 纽力克斯治疗公司 | 2024-09-20 | — | — | CN | disclosed |
| EP-4003965-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | Nurix Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450271-A | Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition | 纽力克斯治疗公司 | 2022-05-06 | — | — | CN | disclosed |
| US-20180127425-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2018-05-10 | — | — | US | disclosed |
| US-20180127425-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2018-05-10 | — | — | US | disclosed |
| US-20180127425-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2018-05-10 | — | — | US | disclosed |
| US-9796719-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2017-10-24 | — | — | US | disclosed |
| US-9796719-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2017-10-24 | — | — | US | disclosed |
| US-9796719-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2017-10-24 | — | — | US | disclosed |
| EP-3010922-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-03-15 | — | — | EP | disclosed |
| EP-3010922-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-03-15 | — | — | EP | disclosed |
| US-20160214986-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2016-07-28 | — | — | US | disclosed |
| US-20160214986-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2016-07-28 | — | — | US | disclosed |
| US-20160214986-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2016-07-28 | — | — | US | disclosed |
| WO-2014202458-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2014-12-24 | — | — | WO | disclosed |
| US-8394796-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-07-12 | — | — | US | disclosed |
| US-8173650-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127425-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ENPP2, TPX2, PRXL2A | CHRNB2 807/4885CHRNA3 2388/4885CHRNA4 2452/4885 |
| US-20160214986-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ENPP2, TPX2, PRXL2A | CHRNB2 807/4885CHRNA3 2388/4885CHRNA4 2452/4885 |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | CHRNB2 636/4885CHRNA3 1118/4885CHRNA4 1491/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | CHRNB2 628/4885CHRNA3 1104/4885CHRNA4 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.